KDEL-grafted chondroitin sulfate CPD/siBcl-2/CK
Sequence: KDEL
| Experiment Id | EXP002476 |
|---|---|
| Paper | Dual Strategies Based on Golgi Apparatus/Endoplasmic Reticulum Targeting and Anchoring for High-Effi |
| Peptide | KDEL-grafted chondroitin sulfate CPD/siBcl-2/CK |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | KDEL grafting ratio on chondroitin sulfate approximately 11% |
| Rna Concentration | In vivo siRNA dose 1 mg/kg where applicable; exact in vitro siRNA concentration not fully specified for luciferase assay |
| Mixing Ratio | CPD/siRNA/CK prepared by CPD/siRNA complexation followed by coating with KDEL-grafted chondroitin sulfate; C/Gu ratios screened, same strategy as CPD/siRNA/CS |
| Formulation Format | polymer/polysaccharide nanocomplex |
| Formulation Components | Cell-penetrating poly(disulfide) (CPD), siRNA, KDEL-grafted chondroitin sulfate (CK); CK provides CD44-associated targeting/Golgi transport and KDEL-mediated ER-directed sorting |
| Size Nm | 167.20 |
| Zeta Mv | -13.60 |
| Model Scope | in_vitro |
| Model Type | in vitro therapeutic gene-silencing assay |
| Cell Lines Or Primary Cells | B16F10 melanoma cells |
| Animal Model | |
| Administration Route | |
| Output Type | in vitro target-gene knockdown and apoptosis |
| Output Value | CPD/siBcl-2/CK showed strong Bcl-2 silencing, increased apoptosis, and inhibited B16F10 proliferation; Western blot band ratio approximately 0.29 for CPD/siBcl-2/CK. |
| Output Units | |
| Output Notes | KDEL-directed sorting produced stronger RNAi and pro-apoptotic activity than CPD/siBcl-2/CS. This is in vitro functional RNA activity, not in vivo delivery success. |
| Toxicity Notes | Good cytocompatibility of nanocomplexes reported in normal cells/HUVEC in supplementary data. |
| Curation Notes |